Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Study Details
Study Description
Brief Summary
The survival of adult patients with standard-risk acute lymphoblastic leukemia(ALL) need to improve. We want to compare the efficacy of haplo-identical hematopoietic stem cell transplantation (HSCT) with chemotherapy for adult(age:18-39 years old) ALL patients in first phase of complete remission (CR1)
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
Although the high complete remission rate (80%-90%) can be achieved, the long-term survival rate of standard-risk adult patients with acute lymphoblastic leukemia(ALL) is only 25%-55% when they receive chemotherapy alone. The survival rate can be further improved uo to 50%-75% when they receive HLA-matched HSCT However, the chance of finding a HLA-matched donor is low, especially in China. Alternative donor such as halpo-identical related donor might be an choice.
Our retrospective analysis showed about 59% overall survival could be achieved when standard-risk adult ALL patients received halpo-identical HSCT.Therefore, we start this randomization controlled trial to compare the efficacy of haplo-identical HSCT with chemotherapy for adult(age:18-39 years old) ALL patients in CR1.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: chemotherapy Drugs: Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d,d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d,d4,d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d,d1-4,d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d,po,d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d,Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years |
Drug: Chemotherapy
Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w,po,6-mercaptopurine 60 mg/m2/d,po,d1-d28,VP(VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
Other Names:
|
Experimental: Haplo-identical HSCT Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT),named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11. |
Procedure: Haplo-identical HSCT
Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
|
Outcome Measures
Primary Outcome Measures
- Disease-free survival [At 2 years from study entry]
Secondary Outcome Measures
- Rate of cumulative incidence of relapse [At 2 years from study entry]
- Overall survival (OS) rate [At 2 years from study entry]
- nonrelapse mortality [At 2 years from study entry]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
acute lymphoblastic leukemia
-
18-39 years old
-
in first complete remission -Adequate hepatic function defined as: total bilirubin ≤2.0 times the institutional upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase(AST) ≤2.5 times the institutional ULN -
-
Adequate renal function defined as creatinine ≤3 times the institutional ULN
-
No uncontrollable infection
-
Performance Status(PS)score 0-2(WHO)
-
Subjects able to provide written informed consent
Exclusion Criteria:
-
having HLA-matched donor
-
high-risk ALL: (1)Ph+ALL (2)Hypodiploidy (3)t(v;11q23) (4) complex karyotype(≥5 chromosome abnormalities)(5)high white blood cell (WBC) count (B-ALL≥30×109/L;T-ALL ≥100×109/L).
-
pregnancy
-
Loss of ability to freely provide consent due to psychiatric or physical illness
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Aerospace Center Hospital | Beijing | Beijing | China | 100044 |
2 | Wuhan Union Hospital | Wuhan | Hubei | China | |
3 | The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China | |
4 | General Hospital of PLA | Beijing | China | ||
5 | Peking Union Hospital | Beijing | China |
Sponsors and Collaborators
- Peking University
- Peking Union Medical College Hospital
- Wuhan Union Hospital, China
- Chinese PLA General Hospital
- The First Affiliated Hospital of Soochow University
- Peking University Aerospace Centre Hospital
Investigators
- Principal Investigator: Xiao-Jun Huang, MD, Peking University People's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ALL-13